Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients-Reference-Cited by-同舟云学术

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

Published:2017-03-28 Issue:6 Volume:13 Page:372-378
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Chow L.W.C.¹²³,Biganzoli L.⁴,Leo A. D.⁴,Kuroi K.⁵,Han H. S.⁶,Patel J.⁶,Huang C.S.⁷,Lu Y.S.⁸,Zhu L.⁹,Chow C.Y.C.³,Loo W.T.Y.²³,Glück S.¹⁰,Toi M.²¹¹

Affiliation:

1. State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute of Applied Medicine and Health; Macau University of Science and Technology; Macau

2. Organisation for Oncology and Translational Research; Hong Kong

3. UNIMED Medical Institute; Hong Kong

4. Sandro Pitigliani Medical Oncology Unit; Hospital of Prato; Italy

5. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital; Tokyo Japan

6. Department of Women's Oncology; H. Lee Moffitt Cancer Center and Research Institute; USA

7. Department of Surgery; National Taiwan University Hospital; Taiwan

8. Department of Oncology; National Taiwan University Hospital; Taiwan

9. Department of Surgery; Shanghai Jiao Tong University; Shanghai China

10. Sylvester Comprehensive Cancer Center, Leonard M. Miller School of Medicine; University of Miami; USA

11. Department of Surgery, Graduate School of Medicine; Kyoto University; Kyoto Japan

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12682/fullpdf

Reference31 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis;Yerushalmi;PLoS One,2014

3. Effect of screening and adjuvant therapy on mortality from breast cancer;Berry;N Engl J Med,2005

4. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review;Howard-Anderson;J Natl Cancer Inst,2012

5. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735;Jones;J Clin Oncol,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients;Current Drug Metabolism;2024-08-16

2. In vitro results with minimal blood toxicity of a combretastatin A4 analogue;Investigational New Drugs;2024-05-17

3. PREVALENCE AND PREDICTIVE FACTORS OF NEUTROPENIA AMONG PATIENTS WITH BREAST CANCER RECEIVING DOXORUBICINCYCLOPHOSPHAMIDE CHEMOTHERAPY AT A CANCER CENTER, SURIN HOSPITAL: A RETROSPECTIVE CASE-CONTROL STUDY;Journal of Southeast Asian Medical Research;2024-04-18

4. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients;The Oncologist;2023-11-23

5. The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis;ecancermedicalscience;2023-11-02